During an interview for an upcoming feature in Life Science Leader, Sanjeev Redkar, Ph.D., cofounder and president of Apollomics (a biopharmaceutical company discovering and developing oncology treatments), discussed the topic of an exit strategy.
While working at his first job at Human Genome Sciences in 1995, Guo-Liang Yu, Ph.D., decided to create The Chinese Biopharmaceutical Association (CBA), one of the largest Chinese American professional associations in the U.S.
While we touch on remote work in Life Science Leader’s annual outlook issue, the responses in this article from four biopharmaceutical CFOs to questions on the subject shed additional light on the challenge that lies ahead for employers.
Two metropolitan areas tend to dominate the discussion when it comes to key biopharmaceutical industry hubs within the United States — Boston and San Francisco. And while these two cities have certainly earned their biopharma bragging rights over the years, one has to wonder how long that will continue. Afterall, just a few years ago biopharmaceutical executives noted it becoming increasingly difficult to attract top talent, as candidates cited “too crowded,” “too expensive,” and a host of other reasons behind their unwillingness to move to places like Boston and San Francisco. But does location (for many roles) even still apply?
Jeffrey Nau, Ph.D., president and CEO of Oyster Point Pharma and subject of upcoming feature in Life Science Leader, explains the scientific rationale behind treating dry eye disease (DED) using nasal spray as a method of delivery.
Jeffrey Nau, Ph.D., president and CEO of Oyster Point Pharma and subject of an upcoming feature in Life Science Leader, shares some of the more personal experiences encountered during life’s journey to the c-suite.
In this special addition to our outlook issue, these finance experts discuss COVID’s effects on the industry and what needs to be done to encourage the allocation of resources to develop and commercialize drugs for common chronic diseases for the future.
For this Beyond The Printed Page installment, six biopharmaceutical company CEOs give their perspectives on companies, people, trends, and technologies they are paying attention to for 2021 and beyond.
Most of us knew that a significant amount of biopharma manufacturing had been offshored to places like China and India. However, most of us (despite Louis Garguilo having written about this as a problem rising on the horizon for years), never thought a supposed trade ally would ever actually use this as a point of leverage to try to get its way.